Bay K8644
| Names | |
|---|---|
| Preferred IUPAC name
Methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.163.930 |
| EC Number |
|
PubChem CID |
|
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C16H15F3N2O4 | |
| Molar mass | 356.301 g·mol−1 |
| Insoluble | |
| Solubility in other solvents | DMSO: 184 mg/mL; methanol and ethanol: 63 mg/mL |
| Hazards | |
| GHS labelling: | |
| Warning | |
| H315, H319 | |
| P264, P280, P302+P352, P305+P351+P338, P321, P332+P313, P337+P313, P362 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
Bay K8644 is a chemical compound that functions as an L-type calcium channel agonist. Bay K8644 is used primarily as a biochemical research tool for this effect. It is a structural analog of nifedipine with positive inotropic activity, and as an aromatic it is highly lipid soluble.